2. Lecture Objectives On completion of the lecture, the student will be able to: – Identify the neurotransmitter systems affected by Alzheimer's disease – Describe the signs and symptoms of various stages of Alzheimer's disease – Explain the primary treatment goals of both pharmacologic and nonpharmacologic therapies for Alzheimer's disease

3. Introduction Alzheimer's disease (AD), first characterized by Alois Alzheimer in 1907, is a gradually progressive dementia affecting: Cognition Behavior Functional status

4. Cognitive Memory loss (poor recall and losing items) Aphasia (inability to communicate normally) Apraxia (motor difficulty) Agnosia (inability to process sensory information) Disorientation (impaired perception of time and unable to recognize familiar people) Impaired executive function

5. Non-cognitive Depression, psychotic symptoms (hallucinations and delusions) Behavioral disturbances (physical and verbal aggression, motor hyperactivity, uncooperativeness, wandering, repetitive mannerisms and activities, and combativeness)

6. Functional Inability to care for self such as: – dressing – bathing – toileting – eating

7. Stages of Alzheimer's Disease DescriptionStages Patient has difficulty remembering recent events. Ability to manage finances, prepare food, and carry out other household activities declines. May get lost while driving. Begins to withdraw from difficult tasks and to give up hobbies. May deny memory problems. Mild (MMSE score 18-26) Patient requires assistance with activities of daily living. Frequently disoriented with regard to time (date, year, season). Recall for recent events is severely impaired. May forget some details of past life and names of family and friends. Functioning may fluctuate from day to day. Patient generally denies problems. May become suspicious or tearful. Loses ability to drive safely. Agitation, paranoia, and delusions are common. Moderate (MMSE score 10-17) Patient loses ability to speak, walk, and feed self. Incontinent of urine and feces. Requires care 24 hours a day, 7 days a week. Severe (MMSE score 0-9)

8. Pathophysiology

9. Characteristics of Alzheimer's Disease Degeneration of cholinergic neurons – The most prominent neurotransmitter – Reduce activity of choline acetyltransferes – Reduce number of cholinergic neurons Cortical atrophy Presence of neurofibrillary tangles Accumulation of neuritic plaques

10. Plaques and Tangles: The Hallmarks of AD The brains of people with AD have an abundance of two abnormal structures: An actual AD plaque An actual AD tangle beta-amyloid plaques, which are dense deposits of protein and cellular material that accumulate outside and around nerve cells neurofibrillary tangles, which are twisted fibers that build up inside the nerve cell AD and the Brain

11. Beta-amyloid Plaques Amyloid precursor protein (APP) is the precursor to amyloid plaque. 1. APP sticks through the neuron membrane. 2. Enzymes cut the APP into fragments of protein, including beta-amyloid. 3. Beta-amyloid fragments come together in clumps to form plaques. 1. 2. 3. AD and the Brain In AD, many of these clumps form, disrupting the work of neurons. This affects the hippocampus and other areas of the cerebral cortex.

12. Neurofibrillary Tangles Neurons have an internal support structure partly made up of microtubules. A protein called tau helps stabilize microtubules. In AD, tau changes, causing microtubules to collapse, and tau proteins clump together to form neurofibrillary tangles. AD and the Brain

13. The Changing Brain in Alzheimer’s Disease No one knows what causes AD to begin, but we do know a lot about what happens in the brain once AD takes hold. Pet Scan of Normal Brain Pet Scan of Alzheimer’s Disease Brain AD and the Brain

14. Preclinical AD Signs of AD are first noticed in the entorhinal cortex, then proceed to the hippocampus. Affected regions begin to shrink as nerve cells die. Changes can begin 10-20 years before symptoms appear. Memory loss is the first sign of AD. AD and the Brain

15. Mild to Moderate AD AD spreads through the brain. The cerebral cortex begins to shrink as more and more neurons stop working and die. Mild AD signs can include memory loss, confusion, trouble handling money, poor judgment, mood changes, and increased anxiety. Moderate AD signs can include increased memory loss and confusion, problems recognizing people, difficulty with language and thoughts, restlessness, agitation, wandering, and repetitive statements. AD and the Brain

16. Severe AD In severe AD, extreme shrinkage occurs in the brain. Patients are completely dependent on others for care. Symptoms can include weight loss, seizures, skin infections, groaning, moaning, or grunting, increased sleeping, loss of bladder and bowel control. Death usually occurs from aspiration pneumonia or other infections. Caregivers can turn to a hospice for help and palliative care. AD and the Brain

17. Diagnosis Rating scale used to assess AD – MMSE – ADAS – SIB – NPI – GDS – CGL

18. Treatment: Alzheimer's Disease Desired Outcomes Nonpharmacologic Therapy Pharmacologic Therapy – Pharmacotherapy for Cognitive Symptoms – Cholinesterase Inhibitors – Antiglutamatergic Therapy – Other Potential Treatment Approaches

19. Desired Outcomes 1.The primary goal of treatment in AD is to symptomatically treat cognitive difficulties and preserve patient function as long as possible 2.Secondary goals include treating the psychiatric and behavioral sequelae that occur as a result of the disease – Current AD treatments have not been shown to prolong life, cure AD, or halt or reverse the pathophysiologic processes of the disorder

20. Non-pharmacologic Therapy Education, communication, and planning are the key nonpharmacologic components of caring for an AD patient.

21. Basic Principles of Care for the Alzheimer's Patient Consider vision, hearing, or other sensory impairmentsFind optimal level of autonomy and adjust expectations for patient performance over time Bring sudden declines in function and the emergence of new symptoms to professional attention Reduce choices, keep requests and demands of the patient simple, and avoid complex tasks that lead to frustration Provide frequent reminders, explanations, and orientation cues. Employ guiding, demonstration, and reinforcement Maintain a consistent, structured environment with stimulation level appropriate to the individual patient Avoid confrontation. Remain calm, firm, and supportive if the patient becomes upset.

22. Pharmacologic Therapy Pharmacotherapy for Cognitive Symptoms Pharmacotherapy of Non-cognitive Symptoms

23. Treatment Options for Cognitive Symptoms in Alzheimer's Disease RecommendationsDisease Consider therapy with a cholinesterase inhibitor Galantamine Donepezil Rivastigmine In mild-moderate disease Antiglutamatergic therapy Memantine In moderate to severe disease

24. Cholinesterase Inhibitors 1.Donepezil 2.Rivastigmine 3.Galantamine – Show similar efficacy and adverse event profiles; generally well tolerated – The most frequent adverse events are mild to moderate gastrointestinal symptoms (nausea, vomiting, and diarrhea) – Other cholinergic side effects are generally dose-related and include urinary incontinence, dizziness, headache, syncope, bradycardia, muscle weakness, salivation, and sweating – Gradual dose titration over several months can improve tolerability – Abrupt discontinuation can lead to worsening cognition and behavior in some patients

25. The mechanism of action Specifically and reversibly inhibits acetylcholinesterase Donepezil Inhibits both butyrylcholinesterase and acetylcholinesterase. Rivastigmine Aselective, competitive, reversible acetylcholinesterase inhibitor and also enhances the action of acetylcholine on nicotinic receptors. Galantamine

26. Pharmacokinetics of Cholinesterase Inhibitors GalantamineRivastigmineDonepezil 7 hr1.5 hr70 hrHalf life 20% kidneyKidneyLiverElimination Yes 2D6,3A4 NoYes 2D6,3A4 Metabolism by CYP450

27. Dosing of Cholinesterase Inhibitors Galantamine ERRivastigmineDonepezil 8mg Qam1.5mg BID5mg/dayInitial dose 4 week steps2 week steps4-6 weeksDose Escalation 24 mg/day12mg /day10 mg /dayMax. Dose Yes NoGiven with Food

28. Antiglutamatergic Therapy Memantine is the only NMDA (N-methyl-D- aspartate)-antagonist currently available Memantine blocks glutamatergic neurotransmission by antagonizing NMDA receptors Glutamate is an excitatory neurotransmitter in the brain implicated in long-term potentiation, a neuronal mechanism important for learning and memory. By blocking NMDA receptors, excitotoxic reactions, which ultimately lead to cell death, may be prevented

29. Antiglutamatergic Therapy Memantine has been studied in patients with moderate and severe AD as monotherapy and in combination with donepezil with modest favorable results on cognition and function. It is currently indicated for use in AD patients with moderate to severe illness.

30. Antiglutamatergic Therapy Memantine has 100% bioavailability regardless of administration with or without food. Protein binding is low. Memantine is not metabolized by the liver and does not inhibit cytochrome P450. Memantine is primarily excreted unchanged in the urine. The half-life ranges from 60 to 80 hours.

31. Antiglutamatergic Therapy The most common adverse events associated with memantine include constipation, confusion, dizziness, headache, hallucinations, coughing, and hypertension

32. Antiglutamatergic Therapy Memantine is likely to be used as monotherapy and also in combination with cholinesterase inhibitors in patients with moderate to severe AD. Memantine should be initiated at 5 mg once a day and increased weekly by 5 mg a day to the effective dose of 10 mg twice daily. Dosing of 10 mg daily is recommended in patients with severe renal impairment

33. Role of Combination Therapy In the only combination treatment trial published to date, patients receiving donepezil were randomized to receive 20 mg/day of memantine or placebo. During the 6-month course of the trial, those randomized to receive combination therapy performed better on a cognitive scale and an activities of daily living scale than those randomized to donepezil plus placebo. A subsequent report concluded that with donepezil-memantine combination therapy, behavioral benefits were also demonstrable on the Neuropsychiatric Inventory. It is important to note that these studies included subjects with MMSE scores of 5 to 14. Data showing donepezil-memantine combination therapy benefits in AD patients with MMSE scores above 14 are lacking.